This early-stage trial, referred to as BD-Ebov, will assess the safety and immune response invoked by the ChAdOx1 BDBV vaccine among 50 healthy adults aged 18 to 55 in Oxford, as stated by the university on Monday.
Here are the details:
• Recruitment has commenced, with vaccinations anticipated to begin in the upcoming weeks, contingent on regulatory clearance.
• The vaccine was created by researchers at Oxford’s Vaccine Group and Pandemic Sciences Institute, utilizing the same viral vector platform as the Oxford/AstraZeneca COVID-19 vaccine.
• The Serum Institute of India, collaborating on the program, reported that it manufactured and stockpiled approximately 620,000 doses of the vaccine candidate within two weeks, and provided 4,000 investigational doses for this early-stage trial.
• In May, the World Health Organization advised prioritizing the ChAdOx1 BDBV vaccine along with a single-dose candidate called rVSV Bundibugyo, developed by the International AIDS Vaccine Initiative, for clinical evaluation in response to the ongoing outbreak.
• The Coalition for Epidemic Preparedness Innovations announced an initial investment of up to $8.6 million for the development of this vaccine.
• Additional clinical trials are being planned in Uganda, pending regulatory approval, through partnerships with the Medical Research Council/Uganda Virus Research Institute and the London School of Hygiene and Tropical Medicine Uganda Research Unit.
• Should the early-stage trial prove successful, CEPI indicated that it would collaborate with Oxford and the Serum Institute to facilitate late-stage studies necessary for seeking emergency-use authorization or complete regulatory approval.
• The partners expressed their commitment to ensuring quick and affordable vaccine access for the affected nations.
